Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jan 15;11(1):27.
doi: 10.21037/atm-22-5266. Epub 2023 Jan 6.

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Jorge Avila  1   2 , José Pablo Leone  3
Affiliations
Editorial

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer

Jorge Avila et al. Ann Transl Med. .
No abstract available

Keywords: Antibody drug conjugates; overall survival (OS); targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-5266/coif). JPL has received research funding from Kazia therapeutics and consulting fees from Minerva Biotechnologies. The other author has no conflicts of interest to declare.

Comment on

References

    1. Breast Cancer Group, Branch of Oncologist, Chinese Medical Doctor Association ; International Medical Exchange Society. Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer. Zhonghua Zhong Liu Za Zhi 2022;44:913-27. - PubMed
    1. de Lartigue J. Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer. OncLive 2022;23.
    1. de Nonneville A, Goncalves A, Mamessier E, et al. Sacituzumab govitecan in triple-negative breast cancer. Ann Transl Med 2022;10:647. 10.21037/atm-22-813 - DOI - PMC - PubMed
    1. Furlanetto J, Marmé F, Loibl S. Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon. Future Oncol 2022;18:3199-215. 10.2217/fon-2022-0407 - DOI - PubMed
    1. Vidula N, Yau C, Rugo HS. Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics. J Clin Oncol 2017;35:abstr 1075.